Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
Series A financing by Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics AG, and others
fefifoliosNovember 16, 2026
